EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models

Salma Begum, Scheldon D Irvin, Carol K Cox, Zhouyang Huang, Justin J Wilson, Jerry D Monroe, Yann Gibert

Investigational New Drugs · 2024

DOI: 10.1007/s10637-024-01479-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Salma Begum und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Biology, University of Mississippi Medical Center, 2500 State Street, Jackson, MS, 39216, USA. Hauptthemen laut MEDLINE: Zebrafish, Histone Deacetylase Inhibitors, Ovarian Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, University of Mississippi Medical Center, Cornell University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is the fifth leading cause of cancer related death in the United States. Cisplatin is a platinum-based anti-cancer drug used against ovarian cancer that enters malignant cells and then damages DNA causing cell death. Typically, ovarian cancer cells become resistant to cisplatin making it necessary to increase subsequent dosage, which usually leads to side-effects including irreversible damage to kidney and auditory system tissue. Ovarian cancer resistance is often associated with upregulation of histone deacetylase (HDAC) enzymes that cause DNA to adopt a closed configuration which reduces the ability of cisplatin to target and damage DNA. Compound B, a platinum(IV) complex with two axial phenylbutyrate (PBA) HDAC inhibitor ligands attached to a cisplatin core, can simultaneously inhibit HDAC activity and damage DNA causing decreased cancer cell viability in cisplatin-sensitive (A2780) and -resistant (A2780cis) ovarian cancer cell lines. However, compound B was not previously evaluated in vivo . As simultaneously inhibiting HDAC-mediated resistance with cisplatin treatment could potentiate the platinum drug’s effect, we first confirmed the anti-cancer effect of compound B in the A2780 and A2780cis cell lines using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide spectrophotometric assay. Then, we used zebrafish embryo and transgenic animal models to comparatively analyze the effect of cisplatin, compound B, and controls on general organismal, auditory, and renal system toxicity, and cancer metastasis. We found that lower dosages of compound B (0.3 or 0.6 µM) than of cisplatin (2.0 µM) could cause similar or decreased levels of general, auditory, and renal tissue toxicity, and at 0.6 µM, compound B reduces cancer metastasis more than 2.0 µM cisplatin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ZebrafishHistone Deacetylase InhibitorsOvarian NeoplasmsAntineoplastic AgentsCisplatinAnimalsFemaleHumansCell Line, TumorProdrugsCell MovementLigandsPlatinum

Stichwörter der Autor:innen

Cisplatin efficacyHDAC inhibitorPlatinum(IV)ToxicityXenograftsZebrafish

Substanzen

Histone Deacetylase InhibitorsAntineoplastic AgentsCisplatinProdrugsLigandsPlatinum

Autor:innen und Institutionen

  • Department of Cell and Molecular Biology, University of Mississippi Medical Center, 2500 State Street, Jackson, MS, 39216, USA.
  • Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY, 14853- 1301, USA.
  • Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, CA, 93106-9510, USA.
  • Department of Cell and Molecular Biology, University of Mississippi Medical Center, 2500 State Street, Jackson, MS, 39216, USA. ygibert@umc.edu.

Förderung

  • NIH HHS
  • University of Mississippi Medical Center
  • Cornell University
  • National Science Foundation
  • NIGMS NIH HHS
  • National Institutes of Health

Zitieren

APA

Begum, S., Irvin, S. D., Cox, C. K., Huang, Z., Wilson, J. J., Monroe, J. D., & Gibert, Y. (2024). Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01479-3

Vancouver

Begum S, Irvin SD, Cox CK, Huang Z, Wilson JJ, Monroe JD, et al. Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01479-3

BibTeX
@article{Begum2024,
  author = {Begum, Salma and Irvin, Scheldon D and Cox, Carol K and Huang, Zhouyang and Wilson, Justin J and Monroe, Jerry D and Gibert, Yann},
  title = {Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models},
  journal = {Investigational New Drugs},
  year = {2024},
  doi = {10.1007/s10637-024-01479-3}
}
Kostenlos starten →